News & Media
News Updates
Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and strengthened global
FDA response expected within six weeks; Company remains focused on 2025 U.S. expansion NEW YORK, August 06, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology
NEW YORK, July 30, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has
Data confirms Company’s ability to detect trace sweat volumes at ultra-micro level System demonstrates resilience across diverse conditions NEW YORK, July 23, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or
NEW YORK, July 16, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new global distribution
NEW YORK, July 15, 2025 – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the addition
Data shows excretion of codeine in fingerprint sweat INBS’ System is viable option for non-invasive diagnostic testing NEW YORK, July 17, 2025 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”),
Understanding drug test detection times is essential when choosing a testing method that aligns with your organization’s safety and compliance goals. While some methods identify drug use days after the
With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technology NEW YORK, June 25, 2025 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the
Employers are rethinking their approach to drug screening. Traditional tests, like urine and saliva, have been the standard for years, but they have logistical challenges and privacy concerns. A newer
NEW YORK, June 18, 2025 — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that Managed Waste Service
Many drug testing programs rely on urine or saliva collection, often chosen because they appear inexpensive. But what looks affordable on paper can become costly, especially once you factor in
Media Contact
For media enquiries, please contact marketing@ibs.inc.
Featured Media
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. Our innovative technology has been featured worldwide in leading news outlets and media platforms.
The Intelligent Fingerprinting Drug Screening System is revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis.
